Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk
Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular risk. Data was collected from patients’ record...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2022-06-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2022-0018 |
| _version_ | 1819000878701477888 |
|---|---|
| author | VAVLUKIS ANA VAVLUKIS MARIJA DIMOVSKI ALEKSANDAR PETRUSHEVSKA GORDANA EFTIMOV ALEKSANDAR DOMAZETOVSKA SASHKA MLADENOVSKA KRISTINA |
| author_facet | VAVLUKIS ANA VAVLUKIS MARIJA DIMOVSKI ALEKSANDAR PETRUSHEVSKA GORDANA EFTIMOV ALEKSANDAR DOMAZETOVSKA SASHKA MLADENOVSKA KRISTINA |
| author_sort | VAVLUKIS ANA |
| collection | DOAJ |
| description | Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular risk. Data was collected from patients’ records, physical examination and blood sampling. Subjects were assigned to rosuvastatin 20 mg per day. Rosuvastatin significantly decreased C-reactive protein (p = 0.045), and increased vascular endothelial growth factor (p = 0.004) and epidermal growth factor (p = 0.009). A multivariate analysis identified total cholesterol (p = 0.027) and vascular endothelial growth factor (p = 0.011) to be independently associated with rosuvastatin treatment. Given beneficial/harmful role of growth factors, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), in cardiovascular disease, one would suggest the need for routine monitoring of growth factor levels, especially in patients on long-term statin therapy. |
| first_indexed | 2024-12-20T22:40:19Z |
| format | Article |
| id | doaj.art-4c016631a3ad4511a8c11e6f0a6ff19b |
| institution | Directory Open Access Journal |
| issn | 1846-9558 |
| language | English |
| last_indexed | 2024-12-20T22:40:19Z |
| publishDate | 2022-06-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj.art-4c016631a3ad4511a8c11e6f0a6ff19b2022-12-21T19:24:29ZengSciendoActa Pharmaceutica1846-95582022-06-0172230331510.2478/acph-2022-0018Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular riskVAVLUKIS ANA0VAVLUKIS MARIJA1DIMOVSKI ALEKSANDAR2PETRUSHEVSKA GORDANA3EFTIMOV ALEKSANDAR4DOMAZETOVSKA SASHKA5MLADENOVSKA KRISTINA61University Ss Cyril and Methodius Faculty of Pharmacy1000Skopje, RN Macedonia2University Ss Cyril and Methodius Faculty of Medicine1000Skopje, RN Macedonia1University Ss Cyril and Methodius Faculty of Pharmacy1000Skopje, RN Macedonia1University Ss Cyril and Methodius Faculty of Pharmacy1000Skopje, RN Macedonia2University Ss Cyril and Methodius Faculty of Medicine1000Skopje, RN Macedonia2University Ss Cyril and Methodius Faculty of Medicine1000Skopje, RN Macedonia1University Ss Cyril and Methodius Faculty of Pharmacy1000Skopje, RN MacedoniaStatins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular risk. Data was collected from patients’ records, physical examination and blood sampling. Subjects were assigned to rosuvastatin 20 mg per day. Rosuvastatin significantly decreased C-reactive protein (p = 0.045), and increased vascular endothelial growth factor (p = 0.004) and epidermal growth factor (p = 0.009). A multivariate analysis identified total cholesterol (p = 0.027) and vascular endothelial growth factor (p = 0.011) to be independently associated with rosuvastatin treatment. Given beneficial/harmful role of growth factors, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), in cardiovascular disease, one would suggest the need for routine monitoring of growth factor levels, especially in patients on long-term statin therapy.https://doi.org/10.2478/acph-2022-0018rosuvastatinvascular endothelial growth factorepidermal growth factorcardiovascular risk |
| spellingShingle | VAVLUKIS ANA VAVLUKIS MARIJA DIMOVSKI ALEKSANDAR PETRUSHEVSKA GORDANA EFTIMOV ALEKSANDAR DOMAZETOVSKA SASHKA MLADENOVSKA KRISTINA Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk Acta Pharmaceutica rosuvastatin vascular endothelial growth factor epidermal growth factor cardiovascular risk |
| title | Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk |
| title_full | Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk |
| title_fullStr | Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk |
| title_full_unstemmed | Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk |
| title_short | Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk |
| title_sort | anti inflammatory and immunomodulatory effects of rosuvastatin in patients with low to moderate cardiovascular risk |
| topic | rosuvastatin vascular endothelial growth factor epidermal growth factor cardiovascular risk |
| url | https://doi.org/10.2478/acph-2022-0018 |
| work_keys_str_mv | AT vavlukisana antiinflammatoryandimmunomodulatoryeffectsofrosuvastatininpatientswithlowtomoderatecardiovascularrisk AT vavlukismarija antiinflammatoryandimmunomodulatoryeffectsofrosuvastatininpatientswithlowtomoderatecardiovascularrisk AT dimovskialeksandar antiinflammatoryandimmunomodulatoryeffectsofrosuvastatininpatientswithlowtomoderatecardiovascularrisk AT petrushevskagordana antiinflammatoryandimmunomodulatoryeffectsofrosuvastatininpatientswithlowtomoderatecardiovascularrisk AT eftimovaleksandar antiinflammatoryandimmunomodulatoryeffectsofrosuvastatininpatientswithlowtomoderatecardiovascularrisk AT domazetovskasashka antiinflammatoryandimmunomodulatoryeffectsofrosuvastatininpatientswithlowtomoderatecardiovascularrisk AT mladenovskakristina antiinflammatoryandimmunomodulatoryeffectsofrosuvastatininpatientswithlowtomoderatecardiovascularrisk |